Vanguard Fiduciary Trust 13F: New $254M Stake in AXON

Vanguard Fiduciary Trust Opens New Position in Axon Enterprise

Vanguard Fiduciary Trust opened a new position in Axon Enterprise, Inc. (NASDAQ:AXON), picking up 452,430 shares during the period. According to its most recent Form 13F filing with the SEC, the newly initiated stake carried an estimated value of $253,636,775.67 based on a cost basis of $507.87 per share. Because this is a brand-new holding for the trust, it reflects a fresh allocation rather than an adjustment to a prior position. This filing captures holdings as of the period ended May 8, 2026, and may not represent the investor's current position today.

Axon Enterprise Stock Moves Higher

Shares of Axon Enterprise traded around $560.61 on Wednesday, sitting well above the 52-week low of $339.01. The public safety technology provider has experienced steady attention from institutional managers and retail investors alike over recent quarters. The latest filing provides a backward-looking glimpse into how major asset managers positioned themselves earlier in the year.

Recent Analyst Updates on Axon

Wall Street firms have continued adjusting their views on the defense technology developer. On June 25, 2026, Citizens reiterated a market outperform rating with a $700.00 price target. Needham maintained a buy rating on July 6, 2026, lifting its target to $750.00 from $600.00. Piper Sandler kept an overweight rating on July 13, 2026, with a $724.00 price target. On August 6, 2026, Barclays kept an overweight rating with a $688.00 target, Piper Sandler maintained an overweight rating with a $732.00 target, Morgan Stanley kept an overweight rating with a $640.00 target, and UBS maintained a neutral rating with a $600.00 target. Later, on September 3, 2026, Argus Research maintained a buy rating while raising its target to $600.00 from $460.00.

Inside Axon Enterprise Operations

Based in Scottsdale, Arizona, Axon Enterprise builds connected hardware and cloud software for law enforcement and public safety agencies globally. Its product lineup includes TASER conducted energy devices, body-worn cameras, in-car video systems, and digital evidence management software like Axon Evidence. The company serves first responders across local, state, federal, and international governments.

What Lies Ahead for Shareholders

Investors tracking institutional flows will look toward upcoming regulatory disclosures and the company's next scheduled earnings release on November 3, 2026. As always, 13F filings are historical documents that show past buying and selling decisions rather than active, real-time trades.